4-[4-(4-Benzylpiperidin-1-yl) but-1-ynyl] phenol (8) and 4-[3-(4-benzylpiperidin-1-yl) prop-1- ynyl] phenol (9) are potent NR1a/2B receptor antagonists (IC50 values 0.17 and 0.10 μM, respectively). Administered intraperitoneally, they both potentiated the activity of l-DOPA in the unilaterally 6-hydroxydopamine-lesioned (6-OHDA) rat, a model of Parkinson's disease. However, compound 9 was not active orally, likely due to rapid first-pass metabolism of ...